In the United States, Wegovy and Zepbound are FDA-approved for chronic weight management, while Ozempic and Mounjaro are indicated for type 2 diabetes
The classical somatomedin hypothesis (Salmon and Daughaday, 1957, foundational sulfation factor research) assumed all peripheral IGF-1 came from this hepatic source
most patients find this effect welcome Digestive changes constipation, loose stools, or mild bloating are common early on Fatigue occasionally reported in the first few weeks Injection site reactions mild itching or redness, typically resolves quickly Side effects are managed through gradual dose titration starting at a low dose and increasing slowly over several weeks
Later, the Modified CTSI was developed by incorporating extrapancreatic complications to further enhance the accuracy of severity evaluation
The benefits extend far beyond the number on the scale: Significant, sustainable fat loss (avg
Speak to a healthcare provider if they persist or feel overwhelming